Full history for every metric is available with a Kvantra account
Changjiang Pharmaceutical Group Co., Ltd. (300391.SZ)
Key financial summary
Financials in CNY| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | CNY m | 725 | 1,215 | 2,362 | 1,615 | 1,198 | 112 | 116 |
| Operating profit | CNY m | -1,331 | -1,300 | |||||
| Net profit | CNY m | -670 | 25 | 49 | -23 | -606 | -628 | -657 |
| EPS reported | CNY | -1.79 | -1.88 | |||||
| Operating cashflow per share | CNY | -0.21 | -0.38 | |||||
| Capex per share | CNY | 0.01 | 0.00 | |||||
| FCF per share | CNY | -0.23 | -0.38 | |||||
| Free cash flow | CNY m | -80 | -175 | |||||
| Net debt | CNY m | 645 | 618 | |||||
| Book value equity | CNY m | -433 | -643 | |||||
| Book value per share | CNY | -1.24 | -1.83 | |||||
| Number of shares | m | 350.33 | 350.22 | |||||
| DPS (TTM paid) | CNY | 0.10 | 0.00 |
Financial summary
Financials in CNY| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | -4.08 | -0.10 | |||||
| P/S LTM | x | 15.82 | 0.57 | |||||
| P/FCF LTM | x | -22.21 | -0.38 | |||||
| EV/EBITDA LTM | x | -1.88 | -0.54 | |||||
| EV/Sales LTM | x | 21.60 | 5.90 | |||||
| Earnings Yield LTM | % | -35.57% | -315.19% | |||||
| FCF Yield | % | -4.50% | -263.30% | |||||
| Quality | ||||||||
| ROE | % | 145.08% | 37.33% | |||||
| ROIC | % | -476.04% | 2105.5% | |||||
| Operating margin | % | -1192.2% | -233.58% | |||||
| Gross margin | % | -7.66% | 0.79% | |||||
| FCF/Sales | % | -71.23% | -127.25% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -90.68% | -58.05% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 2.05% | 0.00% | |||||
| Dividend Growth | % | - | - | |||||
| Payout Ratio | % | -5.77% | -2.75% | |||||
| FCF/Debt | x | -0.12 | -0.27 | |||||
| Net Debt/EBITDA | x | -0.50 | -3.34 | |||||
| EBIT/Net interest | x | -11.96 | -6.34 | |||||
| Net debt/market cap | % | 36.51% | 928.72% | |||||
| Net debt/Equity | x | -1.49 | -0.96 | |||||
| Gross debt/equity | x | -1.51 | -1.00 | |||||
Company overview
Changjiang Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the production and distribution of pharmaceuticals and photovoltaic equipment in China and internationally. It offers photovoltaic equipment, such as laminators and stack welding machines; and Chinese herbal medicines and hollow capsules, as well as engages in pharmaceutical distribution business. The company was formerly known as Kangyue Technology Co., Ltd. and changed its name to Changjiang Pharmaceutical Group Co., Ltd. in March 2023. Changjiang Pharmaceutical Group Co., Ltd. was founded in 1963 and is based in Shiyan, China.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Changjiang Pharmaceutical Group Co., Ltd. (300391.SZ)
Changjiang Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the production and distribution of pharmaceuticals and photovoltaic equipment in China and internationally. It offers photovoltaic equipment, such as laminators and stack welding machines; and Chinese herbal medicines and hollow capsules, as well as engages in pharmaceutical distribution business. The company was formerly known as Kangyue Technology Co., Ltd. and changed its name to Changjiang Pharmaceutical Group Co., Ltd. in March 2023. Changjiang Pharmaceutical Group Co., Ltd. was founded in 1963 and is based in Shiyan, China.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free